



Millenium Biologix Corporation
785 Midpark Drive
Kingston, Ontario
Canada K7M 7G3

FOR IMMEDIATE RELEASE

/NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES/

Millenium Biologix Completes \$15.1 Million Private Placement

- *New Appointments Strengthen Board with Seasoned Directors* -

Kingston, Ontario, CANADA, December 14, 2005

Millenium Biologix Corporation (TSX: MBC) ("Millenium" or "the Company"), a leading biomedical company developing minimally invasive medical devices and skeletal tissue regeneration products for targeted orthopedic uses, today announced it has completed its previously announced \$15 million private placement and appointed new directors.

The private placement consisted of 60,573,000 units of the Company at a price of Cdn. \$0.25 per unit for aggregate gross proceeds of Cdn. \$15,143,250. Each unit consists of one common share of the Company and one-half of one warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of Cdn. \$0.45 for three years. The private placement was completed through a syndicate of investment dealers, co-led by Canaccord Capital Corporation and RBC Capital Markets, and including Clarus Securities Inc. and Toll Cross Securities Inc.

The lead order for the private placement came from BioScience Managers Limited ("BML"), an international venture capital firm focused on life sciences. The Board of the Company has appointed Jeremy Curnock Cook as Chairman.

- Mr. Curnock Cook is currently Executive Chairman of BML. Prior to founding BML, Mr. Curnock Cook created and ran the life science investment activity at Rothschild Asset Management, which had assets under management of over \$1 billion in over 150 investments. Mr. Curnock Cook has served on more than 30 boards of directors in the life science sector. Mr. Curnock Cook holds an MA in Natural Sciences from Trinity College in Dublin.

"The field of orthopedics is becoming increasingly focused on biological devices and tissue engineering, which will ultimately result in creating a large market addressing significant patient populations," said Mr. Curnock Cook. "Millenium, at the forefront of this therapeutic trend, plans to leverage its technology on a global basis and we hope to help them strategically in building a greater product focus."

In conjunction with the financing, a number of strategic initiatives are being undertaken, including:

- The appointment of William J. Tidmore, previous President of Depuy Inc., the world's oldest orthopedic company, as an independent director. Mr. Tidmore brings a wealth of experience in sales & marketing and operational expertise in several countries, including the U.S., Europe, Latin America, Japan and Canada. He led the acquisition of Acromed by DePuy Inc. and directed the growth of the merged entity to become the number two spinal company in the world. Mr. Tidmore holds a Marketing degree from the University of Georgia.

- The appointment of Henry J. Pankratz, previous Deputy Chair of Ernst & Young Canada, as an independent director. Mr. Pankratz brings a strong financial background, and will also be appointed as Chair of the Audit Committee. He spent 38 years with Ernst & Young Canada culminating in leadership roles as Chair, Consulting Services and, ultimately, Deputy Chair of the firm. Mr. Pankratz sits on several boards, including Covington Capital Corporation and Atlantis Systems Corp. Mr. Pankratz holds an Honorary Doctor of Laws from Wilfred Laurier University and is a Fellow of the Institute of Chartered Accountants of Ontario and Certified Management Consultants of Ontario.
- The appointment of Dr. Enda Kenny, former Vice-President, global head of regulatory affairs at Stryker Corporation, one of the largest medical products manufacturers worldwide, as an advisor to the Board. Dr. Kenny brings significant experience bringing orthopedic products through the Food and Drug Administration process, including approval in the U.S., Europe, Canada and Australia for a novel recombinant human protein for treating bone disorders. Dr. Kenny holds a PhD in Biochemistry from Imperial College of Science, Technology and Medicine, University of London.
- A strategic planning review to prioritize programs and optimize utilization of resources. This exercise will focus on shifting emphasis from research to regulatory development and approval of the pipeline products.

Sydney M. Pugh, a founder of the Company, continues as Chief Executive Officer and director. As part of the Company's strategic review, however, Mr. Pugh has decided to accelerate his succession plans for the Chief Executive role and will work closely with the Board in executing the Company's strategic plan and finding his replacement. As previously announced, Dr. Timothy J.N. Smith, also a founder of the Company, becomes Chief Science and Technology Officer. Damian Lamb, Managing Director of Genesys Capital Partners Inc., will remain a director. Graham Strachan and Elizabeth Chen have stepped down from the Board to make room for the new directors. Certain principal shareholders have agreed to vote their Millenium common shares in favour of three nominees to the board of directors of the Company as directed by BML on an ongoing basis.

"We are pleased to have closed this financing, which will continue to drive forward our products through regulatory and commercial development," said Sydney Pugh, CEO of Millenium. "We are also pleased that Jeremy Curnock Cook will join as Chairman and welcome the additional support of Bill Tidmore, Henry Pankratz and Enda Kenny, all with significant industry and operational expertise. We also thank Graham Strachan and Elizabeth Chen for their contributions and support during the past 12 months."

About Millenium Biologix Corporation

Millenium is a leading biomedical company focused on the development and commercialization of next generation, implantable medical devices and skeletal tissue regeneration products for targeted orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. *Skelite™*, Millenium's synthetic bone graft, was launched for commercial sale in June 2003, and *Primacoll™* was commercially launched in Europe in September 2005. *Peptos™* and *ACTES™* (Autologous Clinical Tissue Engineering Systems), Millenium's products addressing the growth factor and tissue engineering markets respectively, are currently in development. For more information about Millenium, please visit www.millenium-biologix.com.

Note: Certain information contained in this press release is forward-looking and is subject to unknown risks or uncertainties. The actual results, performance or achievements of Millenium Biologix Corporation may differ materially from the results, performance or achievements of the Corporation expressed or implied by such forward-looking statements.

For further information, please contact:

General inquiries:

Sheema Inayatulla
Manager, Investor Relations
investor@millenium-biologix.com
T: 613.389.6565 (Toll-free: 866.MBC.3380)

Financial inquiries:

Ian Malone
Chief Financial Officer
ian.malone@millenium-biologix.com
T: 613.389.6565 (Toll-free: 866.MBC.3380)